Purpose:

To evaluate the effectiveness of Xiidra, lifitegrast 5%, in reducing common symptoms of dry eye patients.

Methods:

In this retrospective chart review, 137 patients with dry eye disease were treated with Xiidra. They all completed SPEED surveys preoperatively and postoperatively with a range of 14 to 196 days of treatment. The results of their surveys were analyzed for reduction in dry eye symptoms.

Results:

Frequency and severity of dryness, grittiness, and scratchiness decreased by 27.9% and 25.6%, respectively. Frequency and severity of soreness or irritation decreased by 33.0% and 33.2%, respectively. Frequency and severity of burning or watering decreased by 18.1% and 25.4%, respectiely. Freqency and severity of eye fatigue decreased by 28.4% and 31.3%, respectively. The total SPEED scores decreased by 27.8% overall.

Conclusions:

Xiidra is effective in reducing the frequency and severity of common dry eye symptoms.